Clinical Study

Standard Triple Therapy versus Sequential Therapy in Helicobacter pylori Eradication: A Double-Blind, Randomized, and Controlled Trial

Jaime Natan Eisig, 1 Tomás Navarro-Rodriguez, 1 Ana Cristina Sá Teixeira, 1 Fernando Marcuz Silva, 1 Rejane Mattar, 1 Decio Chinzon, 1 Christiane Haro, 1 Márcio Augusto Diniz, 1 Joaquim Prado Moraes-Filho, 1 Ronnie Fass, 2 and Ricardo Correa Barbuti 1

1 Division of Gastroenterology and Clinical Hepatology, Hospital das Clínicas da FMUSP, 05493-900 São Paulo, SP, Brazil
2 Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH 44109, USA

Correspondence should be addressed to Jaime Natan Eisig; eisig@uol.com.br

Received 5 February 2015; Accepted 22 April 2015

Aim. To compare 10-day standard triple therapy versus sequential therapy as first-line treatment in patients infected with H. pylori.

Methods. One hundred H. pylori positive patients (diagnosed by rapid urease test and histology), with average age of 47.2, M/F = 28/72, were randomized to receive either standard triple treatment (TT) as follows: lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 g, b.i.d. for ten days, or sequential treatment (ST) as follows: lansoprazole 30 mg, amoxicillin and placebo 1.0 g b.i.d for the first five days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and tinidazole 500 mg b.i.d, for the remaining five days. Eradication rates were determined 60 days after treatment by urease, histology, or 13C-urea breath test.

Results. Intention to treat (ITT) analysis, the rate of H. pylori eradication in the TT and ST groups was the same for both regimens as follows: 86% (43/50), 95% CI 93.3 to 73.4%. In Per protocol (PP) analysis, the rate of H. pylori eradication in the TT and ST groups was 87.8% (43/49), 95% CI 94.5 to 75.3% and 89.6% (43/48), 95% CI 95.8 to 77.3%, respectively.

Conclusions. In Brazil, standard triple therapy is as equally effective as sequential therapy in eradicating Helicobacter pylori patients. This study was registered under Clinical Trials with number ISRCTN62400496.

1. Introduction

There are several therapeutic regimens to eradicate H. pylori, involving bismuth, clarithromycin, amoxicillin, furazolidone, nitroimidazole compounds, quinolones, and proton pump inhibitors, in different combinations [1–6].

The triple therapy (proton pump inhibitor, clarithromycin, and amoxicillin) for seven days has been the most widely used regimen, recommended by many national and international consensus meetings [7, 8]. However, over the past several years a considerable drop in the eradication rates of H. pylori has been observed, reaching unacceptable levels (less than 80%) [9, 10]. This phenomenon has been reported by authors from all over the world due to a considerable increase in the prevalence of resistance to clarithromycin and metronidazole [10, 11]. In Brazil, this is also the situation, though in smaller scale [12, 13], because the susceptibility of strains of H. pylori to clarithromycin is still high [14–16]. The resistance to H. pylori varies from one country to another and also in different regions of the same country [17].

In Europe and Asia, a new therapeutic regimen has been used for a few years. It is called sequential therapy, which consists of a double scheme, with a proton pump inhibitor + amoxicillin for five days, followed by a triple therapy with proton pump inhibitor, clarithromycin, and tinidazole for five additional days. The sequential therapy
achieves around 90–94% [18–21] eradication rates. These results, which although are already decreasing in effectiveness [22], have not yet been documented in Latin America [23].

In Brazil, we have not heard of studies using this therapy as the first choice. The aim of this study was to compare the eradication rates of *H. pylori* using sequential therapy versus triple therapy over a period of ten days.

## 2. Methods

### 2.1. Study Design. This is a randomized, double-blind, prospective trial, performed from October 2012 to December 2013, which included patients from the Gastroenterology Department at the University of São Paulo, School of Medicine, Clinical Hospital. Patients at least 16 years old, who underwent an upper endoscopy due to dyspeptic symptoms and were found to have *H. pylori* infection confirmed by the rapid urease test and histology, were enrolled into this study. None of the patients received previous eradication treatment. Exclusion criteria included previous treatment for *H. pylori* and previous use of proton pump inhibitors, antibiotics, or chemotherapy in the four weeks that preceded the beginning of the trial. Patients who had undergone gastrectomy or had history of complicated ulcers (Forrest I and Forrest II), pregnant or breastfeeding women, and patients with consumptive diseases and with uncompensated kidney or heart failure were excluded as well. The study was performed in accordance with the Declaration of Helsinki and was approved by the institutional Ethics Review Board for clinical research. All patients signed an informed consent form. Patients whose *H. pylori* was not eradicated underwent retreatment with another therapeutic regimen.

Patients were randomized into two groups.

(a) Triple therapy (TT) for 10 days (30 mg lansoprazole, 500 mg clarithromycin, and 1.0 g amoxicillin, each administered twice a day).

(b) Sequential therapy (ST) for 10 days (30 mg lansoprazole and 1.0 g amoxicillin and placebo, each administered twice a day for five days, followed by 30 mg lansoprazole, 500 mg clarithromycin, and 500 mg tinidazole, each administered twice a day for the remaining five days).

An independent researcher who was in charge of concealing the medication was responsible for generating a computer-based sequence of random numbers. For each group of patients were prepared pill boxes containing the medications and placebo indistinguishable from active medicine.

### 2.2. Procedures. Patients with dyspeptic symptoms underwent an upper endoscopy. *H. pylori* infection was determined by the rapid urease test [24] and histology [25], using gastric mucosal biopsies of the antrum and body. Patients with positive results in the two methods were included in the trial. *H. pylori* eradication was assessed at least two months after the end of the treatment by urease, histology, and 13C-urea breath test in patients with peptic ulcer [26]. In functional dyspepsia patients, eradication was confirmed only through the 13C-urea breath test. All patients were advised to suspend treatment with proton pump inhibitors or *H*2 receptor antagonists, at least ten days prior to *H. pylori* testing.

The secondary goal of this study was to assess patients’ adherence to treatment and possible adverse effects. Patients’ adherence was determined by using capsule counting and considered satisfactory when more than 90% of the pills were taken. No questionnaires were used in this study.

This study was registered under Clinical Trials with number ISRCTN62400496.

### 2.3. Statistical Analysis. Sample size was calculated using the Fisher exact test with expected eradication rates of 75% and 95% for TT and ST, respectively, considering an 80% power level and 5% significance level.

Descriptive analysis was presented as mean (±standard deviation) for quantitative variables and absolute numbers (percentages) for qualitative variables. The Mann-Whitney test for quantitative variables and Fisher’s exact test for qualitative variables were used to compare the two groups as well as the 95% confidence intervals for the difference between triple therapy and sequential therapy eradication rates.

Intention to treat (ITT) and per protocol (PP) analysis were considered. A *p* value < 0.05 indicates statistical significance.

## 3. Results

### 3.1. Patients. One hundred patients with proved *H. pylori* infection were included in the trial. The baseline demographic and clinical characteristics of patients were similar in the 2 groups (Table 1).

Three patients who were excluded from the PP analysis are as follows: two discontinued because of adverse events (epigastric pain) and one was lost to follow-up. All the patients in both groups adhered to the treatment (>90% of the medication was taken).

### 3.2. Clinical Efficacy. The eradication rates are shown in Table 2. There was no significant difference in the eradication
There was no (ITT: p = 0.677) difference in eradication rates between the Standard Triple Therapy and Sequential Therapy groups, in ITT and PP analysis.

Eighty-five patients were diagnosed with chronic gastritis and 15 with peptic ulcer disease (gastric ulcer or duodenal ulcer). Fifteen, out of the 97 patients who completed the study, had peptic ulcers and 82 had chronic gastritis; of these, 6 patients were using omeprazole, because of dyspeptic symptoms. The overall eradication rates in patients with chronic gastritis and those with peptic ulcer disease were 89.4% and 82,7% observed in a previous study that showed 88,8% and 82,7% since our eradication rates in this trial were the same as we now, we have not observed these epidemiological trends, a tendency to increase its resistance from country to country and from region to region in the same country [17,30]. This variation in resistance can influence the efficacy of H. pylori therapeutic regimens. In Brazil, resistance to clarithromycin is still relatively low, while to metronidazole, it is very common [12–14].

Similar results were also found in other studies that were performed in Latin America [23, 31].

Another relevant factor to be considered is the cost of treatment. In Brazil, triple therapy is available in kits, with three drugs in the same packaging, which makes it easier for the patients to adhere to treatment. The cost of the triple therapy kit is U$ 60,00 on average, while the cost of sequential therapy is approximately U$ 130,00, more than twice as much. Moreover, there is no kit for sequential therapy.

Our trial has few limitations. We have not assessed H. pylori resistance to antibiotics through sensitivity tests, since it is a difficult test to perform in our community and, when available, it is still very costly for the patient.

New trials are necessary to assess if H. pylori in Brazil has a tendency to increase its resistance to clarithromycin. Until now, we have not observed these epidemiological trends, since our eradication rates in this trial were the same as we observed in a previous study that showed 88,8% and 82,7% eradication rates in peptic ulcer and functional dyspeptic patients, respectively [16].

## 5. Conclusion

In conclusion, our findings suggest that sequential therapy has not proven to be superior over triple therapy in eradicating H. pylori infection. Since it has satisfactory eradication
rates, low cost, and less complexity for the patient, triple therapy is still a good first-line regimen to eradicate the *H. pylori* infection in Brazil.

**Conflict of Interests**

The authors have no competing interests.

**Authors’ Contribution**

All authors contributed to the design of the study and have read and approved the final paper. Acquisition of data and quality control were done by Jaime Natan Eisig, Christiane Haro, and Ana Cristina Sá Teixeira. Analysis and interpretation of data were the responsibility of Jaime Natan Eisig, Márcio Augusto Diniz, Fernando Marcuz Silva, Joaquim Prado Moraes-Filho, and Ronnie Fass. Endoscopic examinations were done by Ricardo Correa Barbuti, Tomás Navarro-Rodriguez, and Decio Chinzon. Laboratory tests were the responsibility of Rejane Mattar, and Jaime Natan Eisig was responsible for the paper’s draft.

**Acknowledgments**

The authors thank Mrs. Cibele Villares Lopes (biological technician) who performed the urea breath tests. Drugs are supported by Medley Indústria Farmacêutica, São Paulo, Brazil.

**References**

[1] P. Unge and A. Berstad, "Pooled analysis of anti-*Helicobacter pylori* treatment regimens," *Scandinavian Journal of Gastroenterology, Supplement*, vol. 31, no. 226, pp. 27–40, 1996.

[2] G. A. Pipkin, R. Williamson, and J. R. Wood, “Review article: One-week clarithromycin triple therapy regimens for eradication of *Helicobacter pylori*,” *Alimentary Pharmacology and Therapeutics*, vol. 12, no. 9, pp. 823–837, 1998.

[3] N. Chiba, B. V. Rao, J. W. Rademaker, and R. H. Hunt, “Meta-analysis of the efficacy of antibiotic therapy in eradicating *Helicobacter pylori*,” *American Journal of Gastroenterology*, vol. 87, no. 12, pp. 1716–1727, 1992.

[4] G. Cammarota, R. Cianci, O. Cannizzaro et al., “Efficacy of two-one-week rabeprazole/levofloxacin-based triple therapies for* Helicobacter pylori* infection,” *Alimentary Pharmacology & Therapeutics*, vol. 14, no. 10, pp. 1339–1343, 2000.

[5] M. Amini, H. Khedmat, and F. Yari, “Eradication rate of *Helicobacter pylori* in dyspeptic patients,” *Medical Science Monitor*, vol. 11, no. 4, pp. CR193–CR195, 2005.

[6] R. Vicente, B. Sicilia, S. Gallego, M. J. Revillo, J. Ducón, and F. Gomollón, "*Helicobacter pylori* eradication in patients with peptic ulcer after two treatments failure: A prospective culture-guided study," *Gastroenterologia y Hepatologia*, vol. 25, no. 7, pp. 438–442, 2002.

[7] L. G. Coelho, I. Maguinilk, S. Zaterka, J. M. Parente, M. D. C. F. Passos, and J. P. P. Moraes-Filho, “3rd Brazilian consensus on *Helicobacter pylori*,” *Arquivos de Gastroenterologia*, vol. 50, no. 2, pp. 1–17, 2013.

[8] P. Malfertheiner, F. Megraud, C. A. O’Morain et al., “Management of *Helicobacter pylori* infection—the Maastricht IV/Florence consensus report,” *Gut*, vol. 61, no. 5, pp. 646–664, 2012.

[9] Y. Gumurdulu, E. Serin, B. Özer et al., “Low eradication rate of *Helicobacter pylori* with triple 7–14 days and quadruple therapy in Turkey,” *World Journal of Gastroenterology*, vol. 10, no. 5, pp. 668–671, 2004.

[10] D. Y. Graham and L. Fischbach, “*Helicobacter pylori* treatment in the era of increasing antibiotic resistance,” *Gut*, vol. 59, no. 8, pp. 1143–1153, 2010.

[11] F. Mégrand, “*H pylori* antibiotic resistance: prevalence, importance, and advances in testing,” *Gut*, vol. 53, no. 9, pp. 1374–1384, 2004.

[12] S. Mendonça, C. Ecclissato, M. S. Sartori et al., “Prevalence of *Helicobacter pylori* resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil,” *Helicobacter*, vol. 5, no. 2, pp. 79–83, 2000.

[13] P. Prazeres Magalhães, D. M. De Magalhães Queiroz, D. V. Campos Barbosa et al., “*Helicobacter pylori* primary resistance to metronidazole and clarithromycin in Brazil,” *Antimicrobial Agents and Chemotherapy*, vol. 46, no. 6, pp. 2021–2023, 2002.

[14] J. N. Eisig, F. M. Silva, R. C. Barbuti, T. Navarro-Rodriguez, J. P. P. Moraes-Filho, and J. Pedrazzoli Jr., “*Helicobacter pylori* antibiotic resistance in Brazil: clarithromycin is still a good option,” *Arquivos de Gastroenterologia*, vol. 48, no. 4, pp. 261–264, 2011.

[15] J. N. Eisig, S. B. André, F. M. Silva, C. Hashimoto, J. P. Pinto Moraes-Filho, and A. A. Laudanna, "The impact of *Helicobacter pylori* resistance on the efficacy of a short course pantoprazole based triple therapy,” *Arquivos de Gastroenterologia*, vol. 40, no. 1, pp. 55–60, 2003.

[16] G. Felga, F. M. Silva, R. C. Barbuti, T. Navarro-Rodriguez, S. Zaterka, and J. N. Eisig, “Clarithromycin-based triple therapy for *Helicobacter pylori* treatment in peptic ulcer patients,” *Journal of Infection in Developing Countries*, vol. 4, no. 11, pp. 712–716, 2010.

[17] N. Vakil, “Are there geographical and regional differences in *Helicobacter pylori* eradication?” *Canadian Journal of Gastroenterology*, vol. 17, supplement B, pp. S3B–S32B, 2003.

[18] D. Vaira, A. Zullo, N. Vakil et al., “Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: a randomized trial,” *Annals of Internal Medicine*, vol. 146, no. 8, pp. 556–563, 2007.

[19] L. Gatta, N. Vakil, G. Leandro, F. Di Mario, and D. Vaira, “Sequential therapy or triple therapy for *Helicobacter pylori* infection: systematic review and meta-analysis of randomized controlled trials in adults and children,” *American Journal of Gastroenterology*, vol. 104, no. 12, pp. 3069–3079, 2009.

[20] P. I. Hsu, D.-C. Wu, J.-Y. Wu, and D. Y. Graham, “Is there a benefit to extending the duration of *Helicobacter pylori* sequential therapy to 14 days?” *Helicobacter*, vol. 16, no. 2, pp. 146–152, 2011.

[21] H. Schmiloviz-Weiss, T. Shalev, Y. Chechoulin et al., “High eradication rates of *Helicobacter pylori* infection following sequential therapy: the Israeli experience treating naïve patients,” *Helicobacter*, vol. 16, no. 3, pp. 229–233, 2011.

[22] L. Gatta, N. Vakil, D. Vaira, and C. Scarpignato, “Global eradication rates for *Helicobacter pylori* infection: systematic review and meta-analysis of sequential therapy,” *British Medical Journal*, vol. 347, no. 7920, Article ID f4587, 2013.

[23] E. R. Greenberg, G. L. Anderson, D. R. Morgan et al., “14-day triple, 5-day concomitant, and 10-day sequential therapies for
*Helicobacter pylori* infection in seven Latin American sites: a randomised trial,” *The Lancet*, vol. 378, no. 9790, pp. 507–514, 2011.

[24] R. Mattar, A. F. Dos Santos, J. N. Eisi et al., “No correlation of babA2 with vacA and cagA genotypes of *Helicobacter pylori* and grading of gastritis from peptic ulcer disease patients in Brazil,” *Helicobacter*, vol. 10, no. 6, pp. 601–608, 2005.

[25] R. Mattar, S. B. Marques, A. F. dos Santos, M. D. S. Monteiro, K. Iriya, and F. J. Carrilho, “A possible role of IL-1RN gene polymorphism in the outcome of gastrointestinal diseases associated with *H. pylori* infection,” *Clinical and Experimental Gastroenterology*, vol. 6, no. 1, pp. 35–41, 2013.

[26] J. M. K. da Silva, C. A. Villares, M.-D. S. Monteiro, C. Colaiuto, A. F. dos Santos, and R. Mattar, “Validation of a rapid stool antigen test for diagnosis of *Helicobacter pylori* infection,” *Revista do Instituto de Medicina Tropical de São Paulo*, vol. 52, no. 3, pp. 125–128, 2010.

[27] A. O’Connor, D. Vaira, J. P. Gisbert, and C. O’Morain, “Treatment of *Helicobacter pylori* infection 2014,” *Helicobacter*, vol. 19, supplement 1, pp. 38–45, 2014.

[28] N. Vakil, F. Lanza, H. Schwartz, and J. Barth, “Seven-day therapy for *Helicobacter pylori* in the United States,” *Alimentary Pharmacology and Therapeutics*, vol. 20, no. 1, pp. 99–107, 2004.

[29] W. M. Duck, J. Sobel, J. M. Pruckler et al., “Antimicrobial resistance incidence risk and factors among *Helicobacter pylori*-infected persons, United States,” *Emerging Infectious Diseases*, vol. 10, no. 6, pp. 1088–1094, 2004.

[30] G. M. Buzás, G. Lotz, and A. Kiss, “The epidemiology of clarithromycin resistance of *Helicobacter pylori* infection in Hungary,” *Orvosi Hetilap*, vol. 148, no. 31, pp. 1461–1467, 2007.

[31] V. Yeo-Gamarra, C. Rodriguez-Ulhoa, C. Diaz-Velez et al., “Sa 1914 sequential versus triple standard therapy for *Helicobacter pylori* eradication,” *Gastroenterology*, vol. 144, no. 5, p. S-333, 2013.